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growth of this species. Therefore, it was consid-
ered that an identiﬁcation as M. malmoense ⁄
M. haemophilum with the CM assay indicated the
presence of M. malmoense, although M. malmoense
andM. haemophilum could have been differentiated
further by the AS assay.
In Finland, one GenoType CM strip costs
25 Euros (September 2005), rising to a total cost
of 50 Euros if an additional AS strip is needed.
This is somewhat more expensive than sequenc-
ing (c. 20 Euros per reaction), but the GenoType
assay is faster and can be performed without any
expensive instrumentation.
In conclusion, the GenoType CM assay is a
rapid and reliable method for identiﬁcation of
mycobacteria in a clinical laboratory. Although
the additional information provided by the Geno-
Type AS assay is insufﬁcient to warrant its
uniform use, it is believed that laboratories
without sequencing facilities would beneﬁt from
the availability of this test.
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ABSTRACT
The distribution of ureC was investigated among
294 Escherichia coli isolates, comprising 72 strains
from the E. coli standard reference collection
(ECOR), 62 strains from the diarrhoeagenic E. coli
(DEC) collection, and 160 clinical isolates of Shiga
toxin-producing E. coli (STEC). The ureC gene was
more frequent among STEC isolates harbouring
eae than among those lacking eae (p < 0.0001). All
clinical STEC isolates of serogroups O111 and
O145 contained ureC, but only two of 294 isolates
expressed urease activity. The silencing of urease
expression could not be linked to a stop codon in
ureD. The frequent occurrence of ure genes in eae-
positive STEC isolates makes them valuable
markers for virulence.
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Shiga toxin-producing Escherichia coli (STEC)
strains cause diarrhoea, haemorrhagic colitis
and the haemolytic uraemic syndrome. STEC
strains associated with severe disease are also
termed enterohaemorrhagic E. coli (EHEC) in
order to differentiate them from STEC strains,
Corresponding author and reprint requests: A. W. Friedrich,
Institut fu¨r Hygiene, Universita¨tsklinikum Mu¨nster, Robert-
Koch-Str. 41, 48149 Mu¨nster, Germany
E-mail: alexf@uni-muenster.de
Research Notes 483
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 478–495
which cause mild or no disease in humans [1].
In addition to stx genes, EHEC strains usually
contain eae [2,3], which encodes intimin. STEC
strains that do not contain eae are isolated
mostly from patients with mild diarrhoea and
from asymptomatic carriers [4]. The predomin-
ant EHEC serotype worldwide is E. coli
O157:H7 [1]. However, non-O157 STEC sero-
types, such as O26:H11, O103:H2, O111:H8,
O145:H25 ⁄H28 and their non-motile derivatives,
have been identiﬁed with increasing frequency
in patients with bloody diarrhoea and haemo-
lytic uraemic syndrome [2,3,5–8]. In both E. coli
O157:H7 strains for which the genomes have
been sequenced [9,10], the complete urease gene
operon (ureD, ureA, ureB, ureC, ureE, ureF and
ureG) is present. The ure operon encodes the
three structural subunits (A, B and C) of urease,
as well as the accessory proteins required for
transporting and processing the subunits into
the active form [11]. A study of the distribution of
ure genes among diarrhoeagenic E. coli strains
showed that ureC is associated speciﬁcally with
EHEC and is absent from other intestinal patho-
genic E. coli strains [12]. As previous work was
performed with only a limited number of E. coli
serotypes, the present study was conducted to
determine the prevalence of ureC among well-
deﬁned E. coli reference strain collections and
clinical non-O157 STEC isolates. In addition, the
structure of the ure genes was analysed and an
assessment was made of their ureolytic activity.
The 294 E. coli isolates investigated comprised
72 strains from the E. coli standard reference
collection (ECOR), 62 non-O157 E. coli strains
from the diarrhoeagenic E. coli (DEC) collection
(strain information available at http://www.
shigatox.net/cgi-bin/deca), and 160 STEC strains
isolated in our laboratory between 1996 and 2004
[2–4,7,8,13]. Isolates were O-H serotyped [14] and
tested for sorbitol fermentation and Stx produc-
tion as described previously [15]. Urease produc-
tion was determined in urea degradation broth
(Heipha, Heidelberg, Germany) after overnight
incubation at 37C. Ammonia production was
determined using an ammonia electrode [15]. The
ureC and ureD genes were detected by PCR
[12,16,17], with the PCR amplicons obtained with
representative strains of each serotype being
conﬁrmed by Southern blot hybridisation and
nucleotide sequence analysis as described previ-
ously [16]. The stx and eae genes were detected as
described previously [2,18]. Statistical analysis
was performed using the chi-square test and Epi-
Info v.2002, with p < 0.05 considered to be
statistically signiﬁcant.
All 72 ECOR strains were negative in the PCR
for ureC, but nine of 62 non-O157 DEC strains
possessed ureC (i.e., strains DEC8A, DEC8B,
DEC8D, DEC8E, DEC10A, DEC10B, DEC10E,
DEC10F and DEC11C). Each of these nine strains
contained eae, and seven also contained stx genes.
Among 160 clinical non-O157 STEC isolates, ureC
was signiﬁcantly more frequent (p < 0.0001) in
non-O157 STEC strains that harboured eae
(91 ⁄ 113; 80.5%) than in STEC strains that lacked
eae (2 ⁄ 47; 4.3%) (Table 1). In addition to this
signiﬁcant association between ureC and eae in
non-O157 STEC strains, the presence of ureC was
associated with particular serogoups such as O26,
O111 and O145 (Table 1). Urease activity was
present in only one clinical isolate (Table 1) and
one DEC strain (strain DEC 10A; Table 2). Both
urease-producing strains harboured stx1 and eae
genes. As shown in Table 2, all but one strain
(strain DEC 11C; O45:H2) showed 100% nucleo-
tide sequence homology in their ureC genes with
the corresponding sequence in EDL933 (GenBank
accession no. NC002655). Strain DEC11C had a
point mutation at position 54 (G instead of T), and
Table 1. Distribution of ureC among clinical isolates of
Shiga toxin-producing Escherichia coli (STEC)
Serotype
Clinical diagnosis
eae stx ureC Urease activityHUS D A
O26:H11 17 18 0 35 35 32 1
O26:NM 9 13 0 22 22 20 0
O103:H2 3 15 0 18 18 1 0
O111:H8 2 10 0 12 12 12 0
O111:NM 1 7 0 8 8 8 0
O145:H25 1 0 0 1 1 1 0
O145:H28 2 1 0 3 3 3 0
O145:NM 2 12 0 14 14 14 0
O22:H8 0 0 1 0 1 0 0
O40:H8 0 1 3 0 4 0 0
O40:NM 0 0 1 0 1 0 0
O76:H19 0 1 0 0 1 0 0
O86:NM 0 0 1 0 1 0 0
O91:H21 1 12 0 0 13 0 0
O91:NM 0 2 2 0 4 0 0
O113:H4 0 3 1 0 4 0 0
O113:H21 1 2 0 0 3 0 0
O128:H2 0 6 2 0 8 0 0
O146:H21 0 0 2 0 2 2 0
Orough:NM 0 0 1 0 1 0 0
Orough:HNT 0 1 0 0 1 0 0
ONT:H32 0 0 1 0 1 0 0
ONT:H45 0 0 1 0 1 0 0
ONT:HNT 0 1 0 0 1 0 0
NM, non-motile; ONT, O antigen non-typable; HNT, H antigen non-typable; HUS,
haemolytic uraemic syndrome; D, diarrhoea; A, asymptomatic.
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consequently a nucleotide sequence identity of
99%.
Regarding ureD, three strains (DEC8A, DEC8B
and DEC8C) showed 100% identity with EDL933
and a stop codon at position 742–744, described
previously in EHEC O157:H7. Five DEC reference
strains and one urease-producing clinical isolate
(E02 ⁄ 530; O26:H11) had 99% sequence homology
and a point mutation at position 742 (C instead of
T). Consequently, a stop codon was absent, which
accounts for the phenotypically urease-positive
and urease-negative isolates. Analogous to the
ureC results, DEC11C had one additional point
mutation at position 739 (T instead of C).
A major ﬁnding of the present study was that
80.5% of the eae-positive STEC strains, but only
4.3% of eae-negative STEC strains, possessed ureC.
Moreover, the presence of ureC in clinical isolates is
associated most commonly with known virulent
strains, such as those belonging to serogroupsO26,
O145 and O111, which are generally classiﬁed as
EHEC [7,8,19,20]. DNA sequence analysis indica-
ted that the ureC and ureD genes in non-O157 STEC
strains are identical or related closely to each other
and to those from E. coli O157:H7 strain EDL933.
Therefore, it can be postulated that urease genes
have been acquired recently by non-O157 STEC
strains. In accordance with previous ﬁndings
[16] and observations in EHEC O157:H7 [12,19],
urease activity, as measured by conventional
microbiological methods, is expressed only by a
minority of ure-positive strains, including two
strains of EHEC O26. This is evidence that urease
activity is not a suitable phenotypic marker to use
when searching for STEC, but the reason for this is
unknown. Nakano et al. [17] demonstrated that the
absence of urease activity in EHEC O157:H7 is
caused by a single base substitution (T for C at
position 742 in ureD)which introduces apremature
stop codon [17]. As shown in Table 2, this base
substitution is not present in EHEC O26:H11.
However, two of the strains did not produce
urease, suggesting that other factors are involved
in the non-expression of urease in vitro. This does
not rule out the possibility that urease is produced
by ure-positive strains in vivo, and that this contri-
butes to acid resistance and virulence under
natural conditions.
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ABSTRACT
The efﬁcacy and safety of a combination regimen
including either efavirenz or lopinavir–ritonavir
was examined in a cohort of 65 patients positive for
human immunodeﬁciency virus-1 (HIV-1). Both
the efavirenz (n = 33, 18 anti-retroviral naive) and
lopinavir–ritonavir (n = 32, 15 naive) regimens
achieved signiﬁcant changes from baseline CD4
cell counts and HIV RNA levels after 108 weeks
(p < 0.01). Despite diminished immunological and
virological parameters at study entry, the lopina-
vir–ritonavir group showed greater virological
effects than the efavirenz group after 108 weeks
(median change 3.3 log10, interquartile range
(IQR) 2.2–3.8 log10 vs. 2.4 log10, IQR 0.9–3.3 log10,
respectively, p 0.004). Use of lopinavir–ritonavir,
in contrast to use of efavirenz, was associated with
signiﬁcant hypertriglyceridaemia.
Keywords Anti-retroviral treatment, efavirenz, hyp-
erlipidaemia, immunosuppression, lopinavir–ritonavir
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Recent guidelines concerning the initiation of
therapy against human immunodeﬁciency virus-
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